Vitiligo
☆ Fir-riżultati ta' Stiftung Warentest tal-2022 mill-Ġermanja, is-sodisfazzjon tal-konsumatur b'ModelDerm kien biss ftit inqas milli b'konsultazzjonijiet bit-telemediċina mħallsa.
Vitiligo tas-swaba 'huwa aktar diffiċli biex tikkura minn żoni oħra. Apparti milli huwa kożmetikament unsightly, vitiligo huwa normali u mhux li jittieħed. Fid-dermatoloġija, l-aktar trattament effettiv huwa fototerapija jew trattament bil-laser (excimer) 2-3 darbiet fil-ġimgħa għal mill-inqas sena. Jekk ma tistax tmur l-isptar spiss għal raġunijiet finanzjarji jew għax tkun okkupat, tista 'tipprova magna ta' fototerapija li hija approvata għall-użu fid-dar.
Vitiligo tal-kappell
Vitiligo fuq naħa
References
Il-vitiligo huwa disturb komuni tal-ġilda li jikkawża irqajja tal-ġilda bajda minħabba t-telf ta 'melanoċiti. Riċerka reċenti turi li hija marda awtoimmuni. Filwaqt li ħafna drabi titqies bħala kwistjoni kożmetika, tista 'taffettwa profondament il-benessri mentali u l-ħajja ta' kuljum. Fl-2011, l-esperti klassifikaw tip imsejjaħ segmental vitiligo separatament minn oħrajn.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Pazjenti attivi tal-vitiligo għandhom diversi għażliet ta 'terapija, bħal glukokortikojdi sistemiċi, fototerapija, u immunosoppressanti sistemiċi. Pazjenti stabbli ta 'vitiligo jistgħu jsibu serħan minn kortikosterojdi topiċi, inibituri topiċi tal-kalċineurin, fototerapija, u proċeduri ta' trapjant. Avvanzi riċenti fil-fehim tal-proċessi sottostanti tal-vitiligo wasslu għall-iżvilupp ta 'terapiji mmirati. Bħalissa, l-inibituri JAK huma l-aktar promettenti, li joffru tollerabilità tajba u riżultati funzjonali, minkejja r-riskju li jiġu attivati infezzjonijiet moħbija u effetti sekondarji sistemiċi komuni ma 'aġenti immunosoppressivi oħra. Ir-riċerka li għaddejja għandha l-għan li tidentifika ċitokini ewlenin involuti fl-iżvilupp tal-vitiligo (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF) . L-imblukkar ta 'dawn iċ-ċitokini wera wegħda f'mudelli ta' annimali u f'xi pazjenti. Barra minn hekk, qed isiru investigazzjonijiet dwar miRNA-based therapeutics u adoptive Treg cell therapy.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
M'hemm l-ebda kura magħrufa għall-vitiligo. Għal dawk li għandhom ġilda ħafifa, protezzjoni mix-xemx u għamla huma dak kollu li huwa tipikament rakkomandat. Għażliet oħra ta 'trattament jistgħu jinkludu kremi sterojdi jew fototerapija.
○ Trattament
#Phototherapy
#Excimer laser
#Tacrolimus ointment